MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer

Targeting the PI3K–AKT–mTOR pathway is a promising therapeutic strategy for breast cancer treatment. However, low response rates and development of resistance to PI3K–AKT–mTOR inhibitors remain major clinical challenges. Here, we show that MYC activation drives resistance to mTOR inhibitors (mTORi)...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhin, Jinhyuk, Yemelyanenko, Julia, Chao, Xue, Klarenbeek, Sjoerd, Opdam, Mark, Malka, Yuval, Hoekman, Liesbeth, Kruger, Dinja, Bleijerveld, Onno, Brambillasca, Chiara S., Sprengers, Justin, Siteur, Bjørn, Annunziato, Stefano, van Haren, Matthijs J., Martin, Nathaniel I., van de Ven, Marieke, Peters, Dennis, Agami, Reuven, Linn, Sabine C., Boven, Epie, Altelaar, Maarten, Jonkers, Jos, Zingg, Daniel, Wessels, Lodewyk F.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465700/
https://www.ncbi.nlm.nih.gov/pubmed/37642941
http://dx.doi.org/10.1084/jem.20211743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465700/
https://www.ncbi.nlm.nih.gov/pubmed/37642941
http://dx.doi.org/10.1084/jem.20211743

Ejemplares similares